Aptar (NYSE: ATR) creates dosing, dispensing and packaging products for the global beauty and phara sectors. Over the past 10 years, its revenue grew at revenue grew at 3.7% CAGR while PAT grew at 5.2% CAGR. You would think that with top line and bottom line growth, this would be a good performance. However, it ROE its 2023 was about the same as that in 2012. This standstill return was because there was declining operating and c...
Recent insider selling at AptarGroup could be seen as a negative sign, implying a lower price is reasonable. Despite profitability and growing profits, the level of insider ownership isn't particularly high, warranting caution.
AptarGroup's consistent growth and significant insider ownership are seen as positive indicators for the company's future performance. The company's ability to generate consistent profits is expected to continue adding long-term value for shareholders.
Given the steady ROCE and level of capital employed, AptarGroup may not be a multi-bagger going forward. The stock has returned a total of 38% to shareholders over the last five years, suggesting that investors may have better chances elsewhere.
Despite market headwinds, investors expect AptarGroup to flourish, inflating its P/E ratio. However, with its growth projection matching the market, the rationale behind its high P/E ratio is being questioned. There are risks of share price drop if the P/E ratio doesn't align with growth prediction.
Aptar is a US packaging company that is global leader in drug delivery, consumer product dispensing, and active material science solutions. It achieved revenue and profit growth over the past 11 years, but its ROE in 2022 was what it was in 2012. This was because its operating efficiencies have been declining. You may think that this is a bad performance until you look at SGX’s New Toyo (the holding company for Bursa’s Tien Wah Press). The ROE of bot...
Bank of America analysts express optimism for the packaging sector, seeing Crown Holdings, Sealed Air, WestRock, and AptarGroup as promising investment opportunities.
Mcsnacks H Tupack
RIPPER
:
Game day is just a firm that front-runs its investments. They are one of the few left that do soft dollar arrangements and have side by side conflicting investment strategies.
RIPPER
Mcsnacks H Tupack
:
What u talking about? Idk what GameDay does specifically….I’ve talked to the dude and he’s a nice guy. I don’t subscribe to any such service. I can promise u he is a real guy and not a bot.
RIPPER
Mcsnacks H Tupack
:
I’m guessing ur seeing names and guessing he is simply “long” on all names listed…..it’s my guess, all those names listed above are a good to play wether it’s long or short. Likely if one subscribed those plays would be listed lost / short
AptarGroup Stock Forum
You would think that with top line and bottom line growth, this would be a good performance. However, it ROE its 2023 was about the same as that in 2012. This standstill return was because there was declining operating and c...
You may think that this is a bad performance until you look at SGX’s New Toyo (the holding company for Bursa’s Tien Wah Press). The ROE of bot...
$Alcoa (AA.US)$ $AptarGroup (ATR.US)$ $Aurora Acquisition Corp (AURC.US)$ $BioNexus Gene Lab (BGLC.US)$ $Bluejay Diagnostics (BJDX.US)$ $Boyd Gaming (BYD.US)$ $China Natural Resources (CHNR.US)$ $Enphase Energy (ENPH.US)$ $First Solar (FSLR.US)$ $MGM Resorts International (MGM.US)$ $OKYO Pharma (OKYO.US)$ $Penn Entertainment (PENN.US)$ $Sleep Number (SNBR.US)$ $T. Rowe Price (TROW.US)$ $Wynn Resorts (WYNN.US)$ $Xcel Energy (XEL.US)$
Gap Ups
1. $Oak Street Health (OSH.US)$ -up 26.6%
2. $Baidu (BIDU.US)$ -up 7.5%
3. $BP PLC (BP.US)$ -up 3.2%
4. $Fiserv (FISV.US)$ -up 2.4%
5. $Mitsubishi UFJ Financial Group (MUFG.US)$ -up 1.4%
6. $GlaxoSmithKline (GSK.US)$ -up 0.8%
7. $Microsoft (MSFT.US)$ -up 0.7%
8. $Sanofi (SNY.US)$ -up 0.5%
9. $Activision Blizzard (ATVI.US)$ -up 0.4% ...
No comment yet